Oral Povorcitinib for Extensive Nonsegmental Vitiligo Yields Positive Results in Phase 2b Trial
This new data from the phase 2b trial on povorcitinib could lead to developments in the dermatology space for vitiligo patients.
Source: hcplive.com
Stay updated with breaking news from Extensive Nonsegmental. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
This new data from the phase 2b trial on povorcitinib could lead to developments in the dermatology space for vitiligo patients.